GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » EyePoint Pharmaceuticals Inc (STU:PV3B) » Definitions » Deferred Policy Acquisition Costs

EyePoint Pharmaceuticals (STU:PV3B) Deferred Policy Acquisition Costs


View and export this data going back to 2009. Start your Free Trial

What is EyePoint Pharmaceuticals Deferred Policy Acquisition Costs?

Deferred Policy Acquisition Costs only applies to banks and insurance companies.


EyePoint Pharmaceuticals (STU:PV3B) Business Description

Traded in Other Exchanges
Address
480 Pleasant Street, Suite B300, Watertown, MA, USA, 02472
EyePoint Pharmaceuticals Inc is a pharmaceutical company. It is engaged in developing and commercializing ophthalmic products for the treatment of eye diseases. The company has developed FDA-approved sustained-release treatments in ophthalmology. Its pre-clinical development program is focused on using its core Durasert and Verisome technology platforms to deliver drugs to treat wet age-related macular degeneration, glaucoma, osteoarthritis, and other diseases. Geographically, the firm has operational footprints in the U.S., China, and the UK. It generates a majority of its revenue from the U.S.